Szczegółowy przewodnik wkrótce
Pracujemy nad kompleksowym przewodnikiem edukacyjnym dla ECOG Performance Status. Wróć wkrótce po wyjaśnienia krok po kroku, wzory, przykłady z życia i porady ekspertów.
The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is a standardised clinical scale used to assess the functional capacity and general wellbeing of cancer patients. Developed by Oken and colleagues and published in 1982, the scale was designed to provide a simple, reproducible measure of a patient's ability to perform daily activities and tolerate cancer treatment. The ECOG scale ranges from 0 (fully active, no restriction on activities) to 5 (death). ECOG 1 describes mild restriction of strenuous physical activity but preserved ability to perform light work. ECOG 2 describes patients who are ambulatory and capable of all self-care but unable to perform any work; they are out of bed more than 50% of waking hours. ECOG 3 describes patients capable of only limited self-care, confined to bed or chair more than 50% of waking hours. ECOG 4 describes completely disabled patients who cannot perform any self-care and are totally confined to bed or chair. The ECOG performance status is one of the most important determinants of cancer treatment decisions. Most clinical trials require ECOG 0–1 for enrolment (and some advanced targeted therapy trials accept ECOG 0–2). ECOG 2 patients are generally considered for treatment but with closer toxicity monitoring and dose modification plans. ECOG 3–4 patients are typically ineligible for cytotoxic chemotherapy but may receive best supportive care or palliative systemic therapy where appropriate. The ECOG scale is closely related to but not identical to the Karnofsky Performance Scale (KPS): ECOG 0 corresponds to KPS 100, ECOG 1 to KPS 70–80, ECOG 2 to KPS 50–60, ECOG 3 to KPS 30–40, and ECOG 4 to KPS 10–20.
ECOG 0 = Fully active; ECOG 1 = Restricted strenuous activity, ambulatory; ECOG 2 = Ambulatory, unable to work, out of bed >50% of day; ECOG 3 = Limited self-care, in bed >50% of day; ECOG 4 = Completely disabled, confined to bed/chair; ECOG 5 = Dead
- 1Assess the patient's level of daily activity through clinical observation, patient interview, and collateral history from caregivers. Ask specifically about ability to perform strenuous activity, walking, light housework, and basic self-care.
- 2Determine if the patient is fully active with no restrictions (ECOG 0): can the patient perform all pre-illness activities without limitation?
- 3If restricted but ambulatory: is the patient restricted from strenuous activity but able to perform light work such as light housework or office work? If yes, assign ECOG 1.
- 4If unable to work but ambulatory: can the patient perform all self-care (washing, dressing, eating) and is out of bed more than 50% of waking hours? If yes, assign ECOG 2.
- 5If needing assistance and in bed more than half the day: can the patient perform only limited self-care and is confined to bed or chair for more than 50% of waking hours? If yes, assign ECOG 3.
- 6If completely disabled: is the patient unable to perform any self-care and confined to bed or chair constantly? If yes, assign ECOG 4.
- 7Document the ECOG score at each oncology visit and compare with prior assessments. A worsening ECOG score may signal disease progression, treatment toxicity, or new comorbidity requiring management plan revision.
Eligible for all standard and trial chemotherapy protocols
ECOG 0 patients have the best predicted chemotherapy tolerability and lowest treatment-related mortality. They are eligible for the full range of clinical trial protocols.
May receive modified-dose chemotherapy — excluded from most clinical trials
ECOG 2 patients require dose reduction planning, careful toxicity monitoring, and consideration of single-agent rather than combination chemotherapy. Most Phase III trials exclude ECOG 2 patients.
Cytotoxic chemotherapy usually inappropriate; best supportive care or oral targeted therapy may be considered
ECOG 3 patients have very limited physiological reserve. Most guidelines recommend best supportive care over cytotoxic chemotherapy. Some oral targeted agents may still be appropriate in specific tumour types.
Document ECOG trajectory — decline from 1 to 3 over 6 months suggests significant disease progression or treatment-related decline
Serial ECOG documentation enables detection of functional decline that may warrant treatment change, dose reduction, palliative care referral, or treatment discontinuation.
Mortgage lenders and loan officers use Ecog Performance to structure repayment schedules, compare fixed versus adjustable rate options, and calculate total borrowing costs for residential and commercial real estate transactions across different term lengths.
Personal finance advisors apply Ecog Performance when counseling clients on debt reduction strategies, comparing the mathematical benefit of accelerated payments against alternative investment returns to determine the optimal allocation of surplus cash flow.
Credit unions and community banks rely on Ecog Performance to generate accurate Truth in Lending disclosures, ensure regulatory compliance with TILA and RESPA requirements, and provide borrowers with standardized cost comparisons across competing loan products.
Corporate treasury departments use Ecog Performance to model the cost of revolving credit facilities, term loans, and commercial paper programs, optimizing the company's capital structure and minimizing weighted average cost of debt financing.
Zero or negative interest rate
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in ecog performance calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Balloon payment at maturity
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in ecog performance calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Variable rate mid-term adjustment
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in ecog performance calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
ECOG in immune checkpoint inhibitor therapy
Immunotherapy trials increasingly enrol ECOG 2 patients and show meaningful benefit in some tumour types. Immune checkpoint inhibitors have a different toxicity profile from cytotoxic drugs, and their tolerability in ECOG 2 patients is better characterised than for traditional chemotherapy.
| ECOG Grade | Description | Karnofsky Equivalent | Treatment Implication |
|---|---|---|---|
| 0 | Fully active — no restrictions on activities | 100 | Eligible for all protocols and trials |
| 1 | Restricted strenuous activity; performs light work | 70–80 | Eligible for most protocols; standard dosing |
| 2 | Ambulatory; all self-care; unable to work; out of bed >50% | 50–60 | Modified dose; excluded from most trials |
| 3 | Limited self-care; in bed/chair >50% of waking hours | 30–40 | Cytotoxics usually inappropriate; BSC |
| 4 | Completely disabled; no self-care; totally bedbound | 10–20 | Best supportive care; palliation only |
| 5 | Dead | 0 | — |
What is the ECOG Performance Status used for in oncology?
Ecog Performance is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
What ECOG score is needed for most clinical trials?
In the context of Ecog Performance, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What is the difference between ECOG and Karnofsky Performance Status?
Both assess functional status but on different scales. ECOG uses a 0–5 integer scale, while KPS uses a 0–100 scale in 10-point increments. ECOG 0 ≈ KPS 100; ECOG 1 ≈ KPS 70–80; ECOG 2 ≈ KPS 50–60; ECOG 3 ≈ KPS 30–40; ECOG 4 ≈ KPS 10–20. ECOG is simpler and more widely used in clinical practice; KPS is more granular and commonly used in palliative care and research.
Can ECOG performance status change during treatment?
In the context of Ecog Performance, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Is ECOG subjective?
In the context of Ecog Performance, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Is ECOG 4 the same as ECOG 5?
In the context of Ecog Performance, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
How does ECOG guide palliative care referral?
ECOG 3–4 is a widely recognised indicator for palliative care referral. Patients with ECOG 3 or 4 have poor expected survival with cytotoxic chemotherapy and benefit most from symptom management, goals-of-care discussions, and early palliative care integration. Early palliative care referral in ECOG 3–4 patients has been shown to improve quality of life and sometimes overall survival.
Can ECOG be self-reported by patients?
In the context of Ecog Performance, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Wskazówka Pro
At each consultation, frame the ECOG assessment around a single key question: 'What percentage of waking hours does this patient spend in bed or a chair?' Less than 50% → ECOG 0, 1, or 2; more than 50% → ECOG 3; all waking hours → ECOG 4. This single question cuts through ambiguity at the critical 2/3 boundary.
Czy wiedziałeś?
The ECOG scale was created specifically to standardise patient selection for multi-centre clinical trials so that results from different hospitals could be fairly compared. Before it was introduced, each institution used its own performance status scale, making it nearly impossible to pool or compare trial data across centres. The 1982 publication by Oken et al. solved this problem with five sentences.
Źródła
- ›Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982.
- ›Sorensen JB et al. Performance status assessment in cancer patients: an inter-rater reliability study. J Clin Oncol 1993.
- ›ECOG-ACRIN Cancer Research Group — Performance Status Definitions
- ›Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. NEJM 2010.
- ›MDCalc — ECOG Performance Status